Previous 10 | Next 10 |
2023-07-20 06:36:41 ET Summary Netflix shares fell 7% in premarket trading after Q2 earnings missed revenue expectations but beat profit and subscription forecasts. Tesla shares dropped over 3% premarket after the company failed to boost full-year deliveries guidance and highlight...
2023-07-19 22:37:19 ET Catalent ( NYSE: CTLT ) rose 8.8% in after hours trading after a report that activist investor Elliott Investment Management has taken a significant stake in the contract drug manufacturer. Elliott is pushing for changes in the company's board and has ...
2023-07-19 07:30:00 ET Summary At Laughing Water Capital, our interests are fully aligned with our partners as nearly all of our personal wealth is invested in our strategy. In the second quarter of 2023, Laughing Water Capital returned approximately 13.8% after all fees and expen...
2023-07-11 19:45:00 ET Summary Heading into the Q1 earnings season, we were expecting an ‘earnings recession’ based on a negative Q4 actual growth rate along with analyst estimates forecasting a negative growth rate for both Q1 and Q2. Over the last three months, the...
2023-06-28 18:40:00 ET It seems Catalent (NYSE: CTLT) was apparently the reason why a key drug was refused approval by the Food and Drug Administration (FDA). According to a media report from a leading financial news agency, this is what likely happened. On this disquieting deve...
2023-06-28 10:42:32 ET Catalent ( NYSE: CTLT ) shares extended a four-day decline on Wednesday after confirming that it was the third-party manufacturer linked to the recent FDA rejection of high-dose Eylea developed by Regeneron ( REGN ). The shares of the contract manufa...
2023-06-27 17:25:57 ET Summary Lifecore Biomedical, Inc. is running a sale process. Laughing Water Capital believes upside of 150% is possible over the next three months. The Company's assets are highly strategic, and thus attractive to multiple potential buyers. Capacity will...
2023-06-27 15:09:00 ET Regeneron ( NASDAQ: REGN ) announced Tuesday that the U.S. Food and Drug Administration (FDA) declined to approve an 8 mg dose of its eye disease therapy, aflibercept. The injection at a dose of 2 mg is already marketed in the U.S. as Eylea for conditions ...
2023-06-23 04:59:05 ET Goldman Sachs has rebalanced its ROE Growth basket of 50 stocks selected based on consensus expected return-on-equity growth over the next 12 months. The sector-neutral basket tapped 25 names in the rebalance. The median stock in the basket is projected to ach...
2023-06-20 16:24:57 ET Catalent ( NYSE: CTLT ) said Tuesday that Matti Masanovich has been named senior vice president and chief financial officer. The appointment will be effective July 5, 2023. Prior to joining Catalent, Masanovich served as...
News, Short Squeeze, Breakout and More Instantly...
Expansion adds more temperature-controlled storage and dedicated space for FastChain ® demand-led supply service Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansio...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...